Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,204 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,004 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05859750 | A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer | recruiting | Phase 2 | 78 | AkesoINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06730581 | Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors | not yet recruiting | Phase 2 | 100 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Dec 12, 2024 | clinicaltrials |
| NCT06721286 |
| Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma |
| recruiting |
| Phase 2 |
| 70 |
| Tianjin Medical University Cancer Institute and HospitalOTHER |
| 1 |
| Dec 6, 2024 |
| clinicaltrials |
| NCT06717464 | Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer | active not recruiting | Phase 2 | 110 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT06598033 | Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer | recruiting | Phase 2 / Phase 3 | 50 | Fudan UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06601283 | Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer | recruiting | Phase 2 / Phase 3 | 50 | Fudan UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06700603 | Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer | not yet recruiting | Phase 2 | 48 | Rui-hua Xu, MD, PhDOTHER | 0 | Nov 22, 2024 | clinicaltrials |
| NCT06239532 | HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma | active not recruiting | Phase 2 | 28 | Qilu Hospital of Shandong UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06699459 | Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC(NICRRBTC) | not yet recruiting | Phase 2 | 76 | Sir Run Run Shaw HospitalOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT02919787 | Nordic Pancreatic Cancer Trial (NorPACT) - 1 | active not recruiting | Phase 2 / Phase 3 | 140 | Oslo University HospitalOTHER | 4 | Nov 20, 2024 | clinicaltrials |
| NCT06341764 | Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma | recruiting | Phase 2 | 38 | National Cancer Institute, NaplesOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05254171 | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer(ASPIRE) | recruiting | Phase 2 / Phase 3 | 600 | Panbela Therapeutics, Inc.INDUSTRY | 10 | Nov 6, 2024 | clinicaltrials |
| NCT06669078 | NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer(NALIRIFOX) | not yet recruiting | Phase 2 | 120 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06389760 | Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer | recruiting | Phase 2 | 57 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06662669 | YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Oct 29, 2024 | clinicaltrials |
| NCT06656559 | Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Oct 24, 2024 | clinicaltrials |
| NCT05659914 | Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations | active not recruiting | Phase 2 | 40 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06648525 | Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC | not yet recruiting | Phase 2 | 68 | Harbin Medical UniversityOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT04183712 | Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA | recruiting | Phase 2 | 102 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05462496 | Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer | recruiting | Phase 2 | 25 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT06621095 | Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001) | not yet recruiting | Phase 2 | 104 | RenJi HospitalOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT05638698 | Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer(TESLA) | active not recruiting | Phase 2 | 24 | University of Kansas Medical CenterOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT04205227 | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 137 | ENB Therapeutics, IncINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT06567600 | Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 2 | 43 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06079346 | A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer(STOP-PC) | recruiting | Phase 2 / Phase 3 | 455 | Oncotelic Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06534762 | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study | recruiting | Phase 2 | 260 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06530823 | Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma | not yet recruiting | Phase 2 | 38 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06531291 | Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation | not yet recruiting | Phase 2 | 80 | RenJi HospitalOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06513455 | Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 132 | Harbin Medical UniversityOTHER | 0 | Jul 22, 2024 | clinicaltrials |
| NCT06491472 | Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer | recruiting | Phase 2 | 36 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06298968 | Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 38 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06454448 | Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06359275 | PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients | recruiting | Phase 2 | 81 | Fudan UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06429904 | Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer | active not recruiting | Phase 2 | 31 | Peking Union Medical College HospitalOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT06427460 | Central-boost Ablative Radiation Therapy for Solid Tumors (CBART) | recruiting | Phase 2 | 67 | Changhai HospitalOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT06423170 | A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs | recruiting | Phase 2 | 37 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT06409429 | Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer | not yet recruiting | Phase 2 / Phase 3 | 146 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT03351296 | Two Chemotherapy Regimens Plus or Minus Bevacizumab(BETTER2) | active not recruiting | Phase 2 | 140 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06329947 | A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD | not yet recruiting | Phase 2 | 37 | Rui-hua Xu, MD, PhDOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06296563 | Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC | recruiting | Phase 2 | 20 | Lei ZHAOOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06370754 | Newly Emerging Immunotherapy for Pancreatic Cancer Treatment(FD-IMPACT) | not yet recruiting | Phase 1 / Phase 2 | 117 | Fudan UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06111274 | A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer | recruiting | Phase 2 | 82 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06361030 | Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05984810 | NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101(FLUOPANC-II) | recruiting | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06145074 | Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.(IMPULS) | recruiting | Phase 2 | 30 | Zealand University HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06196788 | Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer(PTCA199-9) | recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06259058 | Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 15, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 16, 2024source: clinicaltrials